• Kymera Therapeutics Inc (NASDAQ: KYMR) commenced an underwritten public offering of 4 million shares of common stock.

  • Underwriters can purchase up to an additional 600k shares.

  • Morgan Stanley, J.P. Morgan, Cowen, and Guggenheim Securities are acting as joint book-running managers for the proposed offering.

  • The proceeds will be used to fund the continued development of KT-474, KT 413, expansion of IRAK4 & IRAKIMiD oncology franchises.

  • Recently, the company announced interim results from the Single Ascending Dose portion of the Phase 1 trial of KT-474 in healthy volunteers.

  • KT-474 has exceeded the Phase 1 target degradation of 85% to date, with robust IRAK4 degradation after a single oral dose lasting for at least six days at all dose levels.

  • The company says that based on existing cash and cash equivalents and marketable securities of $435.2 million and net proceeds from this offering, it will be sufficient to fund our operations into 2025.

  • See the offering prospectus here.

  • Price Action: KYMR shares are down 0.4% at $47 during the premarket session on the last check Tuesday.

See more from Benzinga

  • Click here for options trades from Benzinga

  • Kymera's KT-474 Achieved Sustained IRAK4 Reduction After Single Dose In Healthy Volunteers

  • Kymera Therapeutics' KT-413 Shows Encouraging Preclinical Anti-Cancer Activity

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.